Citadel Advisors
TMDX icon

Citadel Advisors’s Transmedics TMDX Stock Holding History

Citadel Advisors’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.12M Sell
71,600
-12,300
-15% -$1.6M ﹤0.01% 3788
2025
Q4 		$10.2M Sell
83,900
-274,200
-77% -$34.4M ﹤0.01% 3234
2025
Q3 		$40.2M Sell
358,100
-51,800
-13% -$6.06M 0.01% 1597
2025
Q2 		$54.9M Buy
409,900
+118,700
+41% +$13M 0.01% 1172
2025
Q1 		$19.6M Buy
291,200
+54,700
+23% +$3.76M ﹤0.01% 2058
2024
Q4 		$14.7M Buy
236,500
+42,900
+22% +$3.99M ﹤0.01% 2512
2024
Q3 		$30.4M Buy
193,600
+39,600
+26% +$6.1M 0.01% 1673
2024
Q2 		$23.2M Buy
154,000
+111,000
+258% +$13.3M ﹤0.01% 1852
2024
Q1 		$3.18M Buy
43,000
+12,000
+39% +$989K ﹤0.01% 4678
2023
Q4 		$2.45M Sell
31,000
-16,600
-35% -$1M ﹤0.01% 5008
2023
Q3 		$2.61M Buy
47,600
+25,500
+115% +$1.84M ﹤0.01% 4742
2023
Q2 		$1.86M Sell
22,100
-1,800
-8% -$138K ﹤0.01% 5276
2023
Q1 		$1.81M Sell
23,900
-4,600
-16% -$318K ﹤0.01% 5579
2022
Q4 		$1.76M Sell
28,500
-8,400
-23% -$447K ﹤0.01% 5716
2022
Q3 		$1.54M Buy
36,900
+20,600
+126% +$896K ﹤0.01% 6104
2022
Q2 		$513K Buy
16,300
+3,900
+31% +$104K ﹤0.01% 8584
2022
Q1 		$334K Sell
12,400
-4,300
-26% -$77K ﹤0.01% 10342
2021
Q4 		$320K Sell
16,700
-68,900
-80% -$1.73M ﹤0.01% 10781
2021
Q3 		$2.83M Buy
85,600
+55,000
+180% +$1.68M ﹤0.01% 5508
2021
Q2 		$1.01M Buy
30,600
+3,700
+14% +$103K ﹤0.01% 8335
2021
Q1 		$1.12M Buy
+26,900
New +$828K ﹤0.01% 7839

Other funds holding TMDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's TMDX Position: Q1 2026 in Review

Citadel Advisors reduced its Transmedics (TMDX) stake by 57% in Q1 2026, selling an estimated $10.6M and leaving 61,601 shares worth $6.12M. The position accounts for ﹤0.01% of the portfolio, ranked #4015.

Citadel Advisors first reported a position in TMDX in Q2 2019 and has held it in 24 quarters since. The position peaked at $41M in Q1 2025. 414 funds tracked by Wall St. Rank hold TMDX as of Q1 2026.

  • Citadel Advisors held 61,601 shares of Transmedics worth $6.12M as of Q1 2026.
  • Citadel Advisors sold 81,646 Transmedics shares in Q1 2026, an estimated $10.6M.
  • Transmedics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4015 holding.
  • Citadel Advisors first reported a position in Transmedics in Q2 2019 and has held it in 24 quarters since.
  • Citadel Advisors's Transmedics position peaked at $41M in Q1 2025.
  • 414 funds tracked by Wall St. Rank held Transmedics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.